Efficacy of triglyceride lowering
The prespecified primary end point of this trial was the least squares mean percent reduction in triglycerides from baseline after 12 weeks of evinacumab exposure (combination of DBTP and SBTP) in cohort 3. The mean (s.e.m.) percent reduction in triglycerides from baseline in cohort 3 was –27.1% (37.4) (95% confidence interval (CI) –71.2 to 84.6); however, the log-transformed triglyceride values were not normally distributed, making use of mean percent change in triglyceride levels a less-than-ideal end point. Therefore, we also performed a post hoc analysis using median percent reductions in triglyceride values (results presented below).During the DBTP, the three cohorts were heterogeneous in the triglyceride-lowering response observed. Notably, the LPL-deficient cohort 1 exhibited substantially less response to evinacumab than the other two cohorts (Fig. 